Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC).

15 Oct 2013

Viewpoints: 'Death throes' of health law opponents; Ryan's plan on entitlements may offer way out of budget crisis

Politically, the biggest challenges facing the ACA are behind us. By my count, the law has already survived three near-death experiences: the Democrats' loss of a filibuster-proof Senate majority with the election of Scott Brown in Jan. 2010, the Supreme Court's June 2012 decision upholding (with one exception) the law's constitutionality, and President Obama's re-election last Nov. Much of what we see going on in Washington now is the death throes of the opposition, especially now that Americans are beginning to sign up for coverage (John McDonough, 10/9).

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Surgeons at UC San Diego Health System have performed the region's first robotic gastrectomy, a potentially lifesaving procedure to remove a section of the stomach after a diagnosis of gastric cancer. Aided by a da Vinci robot, surgeons remove the diseased tissue, perform a delicate reconstruction and remove local lymph nodes for further testing.

3 Oct 2013

Black, Hispanic children with abdominal pain more likely to receive any analgesic in ER pain management

Pediatric researchers have found race- and ethnicity-based disparities in pain management and length of stay among children who came to hospital emergency departments for treatment of abdominal pain. A study team reported on their analysis of a national database of hospital visits in the October issue of Pediatrics.

24 Sep 2013

Coeliac disease on rise in Scots children

More children than ever before are living with a debilitating digestive disease, research has shown.

18 Sep 2013

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Amgen today announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer.

12 Sep 2013

Electroacupuncture treatment improves visceral hypersensitivity in irritable bowel syndrome

Irritable bowel syndrome patients extensively suffer from chronic visceral hypersensitivity, with involvement of all levels of the brain-gut axis, as well as various neurotransmitters.

12 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Updated guidelines for management of acute pancreatitis

Updated guidelines on the management of acute pancreatitis, a condition that causes acute inflammation of the pancreas, appear in the September issue of The American Journal of Gastroenterology.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

Swiss researchers report an increase risk of inflammatory bowel disease (IBD) relapse in patients during heat wave periods. The study published in The American Journal of Gastroenterology also found an increase of infectious gastroenteritis during heat waves, with the strongest impact following a 7 day lag time after the heat wave.

14 Aug 2013

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

Abdominal Pain News and Research

Further Reading

AstraZeneca announces Phase III study results of naloxegol in patients with non-cancer pain

Viewpoints: 'Death throes' of health law opponents; Ryan's plan on entitlements may offer way out of budget crisis

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Black, Hispanic children with abdominal pain more likely to receive any analgesic in ER pain management

Coeliac disease on rise in Scots children

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Electroacupuncture treatment improves visceral hypersensitivity in irritable bowel syndrome

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Updated guidelines for management of acute pancreatitis

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

FDA grants Priority Review designation to sNDA for Nexavar tablets

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

Patients with IBS-D treated with eluxadoline achieve better clinical response

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News